| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
China Resources Double-Crane Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥23.82 |
| 52 Week High | CN¥24.27 |
| 52 Week Low | CN¥14.80 |
| Beta | 0.14 |
| 11 Month Change | 9.12% |
| 3 Month Change | 25.50% |
| 1 Year Change | 36.43% |
| 33 Year Change | 97.84% |
| 5 Year Change | 91.63% |
| Change since IPO | 62.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600062 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.2% | 15.7% | 15.5% |
| 1Y | 36.4% | -1.6% | 1.2% |
Return vs Industry: 600062 exceeded the CN Pharmaceuticals industry which returned -1.6% over the past year.
Return vs Market: 600062 exceeded the CN Market which returned 1.2% over the past year.
Price Volatility
| 600062 volatility | |
|---|---|
| 600062 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 4.5% |
Stable Share Price: 600062 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600062's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 12,269 | Wenchao Lu | www.dcpc.com |
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, and other.
China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600062 fundamental statistics | |
|---|---|
| Market cap | CN¥24.46b |
| Earnings (TTM) | CN¥1.39b |
| Revenue (TTM) | CN¥10.31b |
17.5x
P/E Ratio2.4x
P/S RatioIs 600062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600062 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.31b |
| Cost of Revenue | CN¥4.60b |
| Gross Profit | CN¥5.71b |
| Other Expenses | CN¥4.32b |
| Earnings | CN¥1.39b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 26, 2024
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 55.40% |
| Net Profit Margin | 13.53% |
| Debt/Equity Ratio | 2.0% |
How did 600062 perform over the long term?
See historical performance and comparison